{
  "schemaVersion": 1,
  "id": "research-361",
  "slug": "361-what-an-mri-showed-about-liver-fat-in-synchronize-masld",
  "title": "What an MRI showed about liver fat in SYNCHRONIZE-MASLD",
  "catalogLabel": "Survodutide",
  "productCollection": "https://heritagebiolabs.com/research-library/products/survodutide",
  "productHandles": [
    "survodutide-700"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/survodutide-700"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 362,
  "sourceYears": [
    2024,
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids linked by peptide bonds. Some can activate receptors that change how the body processes nutrients. Survodutide is an investigational glucagon and GLP-1 receptor agonist peptide. A phase 3 study reported in 2026 asked whether it changed liver fat and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, or MASLD. [1]",
    "The researchers randomly assigned 216 adults to survodutide or placebo. Participants had evidence from noninvasive tests of liver inflammation or scarring, or a biopsy confirming metabolic dysfunction-associated steatohepatitis. The investigators used an MRI measurement known as proton density fat fraction to estimate the proportion of the liver measurement attributable to fat. One primary outcome was the proportion of participants with a relative reduction of at least 30% in that measurement at 48 weeks. The other primary outcome was percentage change in body weight over the same period. [1]",
    "In the analysis intended to reflect treatment assignment, 68.5% of participants in the survodutide group and 28.6% in the placebo group reached the liver fat threshold. Average weight change in that analysis was −8.7% and −1.4%, respectively. The paper also reported results under a different statistical approach, which gave larger estimated changes. The numbers should be read with the analysis to which they belong, since different assumptions about events during the trial can affect the estimate. [1]",
    "The study’s most frequently reported adverse events with survodutide involved the digestive system. The authors described them as generally mild to moderate. The trial recruited in the United States and Spain and followed participants for 48 weeks. These details help define the setting in which the reported changes and events occurred. [1]",
    "Liver fat is one feature of metabolic liver disease. A reduction measured by MRI gives information about that feature, while liver tissue measurements assess inflammation and scarring more directly. The MRI result also does not count longer-term complications such as decompensation or a need for transplantation. Separate investigations ask those questions with different outcomes. SYNCHRONIZE-MASLD provides a controlled comparison for the two measures it specified, and its results should be read as evidence about the investigational peptide under the trial conditions. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Lee M. Kaplan et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine (publication 2026-06-07).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42252333/"
    },
    {
      "number": 2,
      "citation": "Arun J. Sanyal et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England Journal of Medicine (publication 2024-06-07).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38847460/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/361-what-an-mri-showed-about-liver-fat-in-synchronize-masld",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/361-what-an-mri-showed-about-liver-fat-in-synchronize-masld.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/361-what-an-mri-showed-about-liver-fat-in-synchronize-masld.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 073 - Survodutide and TB-500.docx",
    "sourceArticleNumber": 361,
    "contentSha256": "dc88bd8ca090b59ca65df941eb4ed0acfd99ca9fb9a94f724d5634e8f806095d",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
